Catalog No. L10-901
|Catalog No.||Pack Size||Price (USD)|
Novel, potent and selective inhibitor of the leucine-rich repeat kinase-2 (LRRK2), IC50 = 1.28 nM. Also inhibits G2019S mutant LRRK2, IC50 = 1.85 nM (1). Attenuates the neuronal damage elicited by the action of LRRK2 G2019S mutant in primary human neurons (EC50 = 1 nM) (1). The G2019S mutant is a common mutation found in familial Parkinson’s disease patients (2). Cell permeable.
1. LH Wang et al. J. Immunol. 1999 162:3897
2. N Meydan et al. Nature 1996 379:645
CAS Registry Number:
C22H25ClN6O4S ∙ HCl
≥98% (TLC); NMR (Conforms)
May be dissolved in DMSO (50 mg/ml)
N-[-[[5-Chloro-2-[[2-methoxy-4-(4-morpholinyl) phenyl] amino]-4-pyrimidinyl] amino] phenyl] methanesulfonamide hydrochloride
Storage and Stability:
Store desiccated as supplied at ambient temperature for up to 1 year. Store solutions at -20oC for up to 1 month.
There are no related publications available for this product.